Endocan, a potential prognostic and diagnostic biomarker of acute leukemia

[1]  Jingru Zhang,et al.  Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. , 2013, Carcinogenesis.

[2]  Z. Radisavljevic,et al.  Increased Angiogenesis-associated Poor Outcome in Acute Lymphoblastic Leukemia: A Single Center Study , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  Ø. Bruserud,et al.  Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia , 2011, Hematology.

[4]  Ø. Bruserud,et al.  Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation , 2010, European journal of haematology.

[5]  R. Kalluri,et al.  Contribution of bone microenvironment to leukemogenesis and leukemia progression , 2009, Leukemia.

[6]  B. Wegiel,et al.  The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia , 2009, Leukemia.

[7]  Ø. Bruserud,et al.  Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators , 2009, British journal of haematology.

[8]  A. Albini,et al.  Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[9]  A. Harris,et al.  Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. , 2009, Frontiers in bioscience.

[10]  G. Thurston,et al.  VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis , 2008, British Journal of Cancer.

[11]  J. Komorowski,et al.  Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. , 2007, Experimental cell research.

[12]  M. Lyon,et al.  Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. , 2006, Biochimica et biophysica acta.

[13]  Ø. Bruserud,et al.  Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. , 2005, Current cancer drug targets.

[14]  R. Kolesnick,et al.  Ceramide synthesis and metabolism as a target for cancer therapy. , 2004, Cancer letters.

[15]  A. Janin,et al.  Overexpression of endocan induces tumor formation. , 2003, Cancer research.

[16]  R. Lotan,et al.  N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). , 2003, Leukemia research.

[17]  A. Karsan,et al.  Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia , 2002, American journal of hematology.

[18]  W-X Guo,et al.  N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes , 2002, Leukemia.

[19]  Christopher C W Hughes,et al.  Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. , 2002, Microvascular research.

[20]  J. Tavernier,et al.  ESM-1 Is a Novel Human Endothelial Cell-specific Molecule Expressed in Lung and Regulated by Cytokines* , 1996, The Journal of Biological Chemistry.

[21]  S. Ménard,et al.  N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. , 1993, Cancer research.